Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy

Yanyan Lou, Julian A. Marin-Acevedo, Prakash Vishnu, Rami Manochakian, Bhagirathbhai Dholaria, Aixa Soyano, Yan Luo, Yan Zhang, Keith L. Knutson

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Immune checkpoint inhibitors have changed the treatment paradigm for patients with cancer. Though a majority of patients tolerate treatment, some develop hematologic toxicities, including eosinophilia. Eosinophilia has been associated with better responses in some patients with melanoma, but this has not been investigated in non-small-cell lung cancer. We present a case of a woman with metastatic lung adenocarcinoma who developed asymptomatic hypereosinophilia after initiation of nivolumab. Her eosinophil count temporarily decreased after transiently stopping the medication, but increased again after re-initiation. She had a favorable tumor response to therapy. This exemplifies the potential role of eosinophilia as a peripheral, readily available biomarker of favorable response to immunotherapy in patients with lung cancer. Awareness of this manifestation is important.

Original languageEnglish (US)
Pages (from-to)577-584
Number of pages8
JournalImmunotherapy
Volume11
Issue number7
DOIs
StatePublished - May 2019

Keywords

  • biomarker
  • hypereosinophilia
  • immune-related adverse events
  • lung cancer
  • nivolumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy'. Together they form a unique fingerprint.

  • Cite this